Neutropenia

Publication Title: 
Cancer Investigation

Paclitaxel is an active agent for adenocarcinomas and squamous cell carcinomas of the esophagus and is a radiation sensitizer. We sought to investigate the toxicity and complete response rate of paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Forty-one patients with esophageal cancer were studied, 29 with adenocarcinomas and 12 with squamous cell cancers. Twelve patients had tumor extension into the proximal stomach and/or abdominal adenopathy.

Author(s): 
Safran, H.
Gaissert, H.
Akerman, P.
Hesketh, P. J.
Chen, M. H.
Moore, T.
Koness, J.
Graziano, S.
Wanebo, H. J.
Publication Title: 
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

BACKGROUND: Artemisinin-based combination therapies are rapidly being adopted for the treatment of malaria in Africa; however, there are limited data on their safety and efficacy among human immunodeficiency virus (HIV)-infected populations. METHODS: We compared malaria treatment outcomes between cohorts of HIV-infected and HIV-uninfected children in Uganda who were observed for 18 and 29 months, respectively. Malaria was treated with artesunate plus amodiaquine, and outcomes were assessed using standardized guidelines.

Author(s): 
Gasasira, Anne F.
Kamya, Moses R.
Achan, Jane
Mebrahtu, Tsedal
Kalyango, Joan N.
Ruel, Theodore
Charlebois, Edwin
Staedke, Sarah G.
Kekitiinwa, Adeodata
Rosenthal, Philip J.
Havlir, Diane
Dorsey, Grant
Publication Title: 
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

BACKGROUND: Fears of emerging artemisinin resistance in western Cambodia have prompted a series of clinical trials investigating whether slow responses to antimalarial treatment can be overcome by increasing doses of drug. METHODS: Patients with uncomplicated malaria were allocated 1 of 3 oral artesunate monotherapy regimens (2, 4, or 6 mg/kg/day for 7 days) and were observed for 42 days. A series of safety measures, including complete blood count on days 0, 3, 6, and 14, was implemented because of a lack of safety data for these experimental doses.

Author(s): 
Bethell, Delia
Se, Youry
Lon, Chanthap
Socheat, Duong
Saunders, David
Teja-Isavadharm, Paktiya
Khemawoot, Phisit
Darapiseth, Sea
Lin, Jessica
Sriwichai, Sabaithip
Kuntawungin, Worachet
Surasri, Sittidech
Lee, Sue J.
Sarim, Ses
Tyner, Stuart
Smith, Bryan
Fukuda, Mark M.
Publication Title: 
PloS One

BACKGROUND: The emergence of artemisinin resistance has raised concerns that the most potent antimalarial drug may be under threat. The currently recommended daily dose of artesunate (AS) is 4 mg/kg, and is administered for 3 days together with a partner antimalarial drug. This study investigated the impact of different AS doses on clinical and parasitological responses in malaria patients from an area of known artemisinin resistance in western Cambodia. METHODS: Adult patients with uncomplicated P.

Author(s): 
Bethell, Delia
Se, Youry
Lon, Chanthap
Tyner, Stuart
Saunders, David
Sriwichai, Sabaithip
Darapiseth, Sea
Teja-Isavadharm, Paktiya
Khemawoot, Phisit
Schaecher, Kurt
Ruttvisutinunt, Wiriya
Lin, Jessica
Kuntawungin, Worachet
Gosi, Panita
Timmermans, Ans
Smith, Bryan
Socheat, Duong
Fukuda, Mark M.
Publication Title: 
Journal of Alternative and Complementary Medicine (New York, N.Y.)

OBJECTIVES: The objective of this study was to investigate the effect of acupuncture administered during myelosuppressive chemotherapy on white blood cell (WBC) count and absolute neutrophil count (ANC) in patients with ovarian cancer. DESIGN: This study is a pilot, randomized, sham-controlled clinical trial. Patients received active acupuncture versus sham acupuncture while undergoing chemotherapy. A standardized acupuncture protocol was employed with manual and electrostimulation.

Author(s): 
Lu, Weidong
Matulonis, Ursula A.
Doherty-Gilman, Anne
Lee, Hang
Dean-Clower, Elizabeth
Rosulek, Andrew
Gibson, Carolyn
Goodman, Annekathryn
Davis, Roger B.
Buring, Julie E.
Wayne, Peter M.
Rosenthal, David S.
Penson, Richard T.
Publication Title: 
Homeopathy: The Journal of the Faculty of Homeopathy

BACKGROUND: Severe chronic neutropenia (SCN) places the sufferer at increased risk of bacterial infection, often requiring emergency hospital admission and long-term antibiotic treatment. METHOD: A single clinical case study of idiopathic SCN in a boy of 3 years and 8 months at the start of treatment individualized, classical homeopathic treatment was given. Neutrophil count was measured at: 5, 17, 21, 29 and 41 months after commencing treatment. RESULTS: Low neutrophil count (0.6 and 0.3 x 10(9)/L) was documented for 17 months prior to commencing treatment.

Author(s): 
Poole, Jennifer
Publication Title: 
Journal of Alternative and Complementary Medicine (New York, N.Y.)

BACKGROUND: Reiki therapy is documented for relief of pain and stress. Energetic healing has been documented to alter biologic markers of illness such as hematocrit. True random number generators are reported to be affected by energy healers and spiritually oriented conscious awareness. METHODS: The patient was a then 54-year-old severely ill man who had hepatitis C types 1 and 2 and who did not improve with conventional therapy. He also suffered from obesity, the metabolic syndrome, asthma, and hypertension.

Author(s): 
Morse, Melvin L.
Beem, Lance W.
Publication Title: 
Journal of Alternative and Complementary Medicine (New York, N.Y.)

BACKGROUND: Reiki therapy is documented for relief of pain and stress. Energetic healing has been documented to alter biologic markers of illness such as hematocrit. True random number generators are reported to be affected by energy healers and spiritually oriented conscious awareness. METHODS: The patient was a then 54-year-old severely ill man who had hepatitis C types 1 and 2 and who did not improve with conventional therapy. He also suffered from obesity, the metabolic syndrome, asthma, and hypertension.

Author(s): 
Morse, Melvin L.
Beem, Lance W.
Publication Title: 
The Oncologist

Optimal oncologic care of older men with prostate cancer, including effective prevention and management of the disease and treatment side effects (so-called best supportive care measures) can prolong survival, improve quality of life, and reduce depressive symptoms. In addition, the proportion of treatment discontinuations can be reduced through early reporting and management of side effects. Pharmacologic care may be offered to manage the side effects of androgen-deprivation therapy and chemotherapy, which may include hot flashes, febrile neutropenia, fatigue, and diarrhea.

Author(s): 
Scotté, Florian
Subscribe to RSS - Neutropenia